GenSight Biologics, which is developing a gene therapies for rare retinal diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The year's other retinal gene therapy biotech, Spark Therapeutics (ONCE), is currently the best-performing IPO of 2015, up 170% from its offer price.
The Paris, France-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol GNST. Leerink Partners, Evercore Partners and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.
